PharmAla Biotech Holdings Inc. (MDXXF) has secured a significant agreement to supply its LaNeo MDMA for a clinical trial at Harvard’s McLean Hospital, a renowned institution in neuroscience and psychiatric research. This partnership highlights PharmAla’s commitment to supporting MDMA-based clinical research and expanding its reach across the U.S.